Kohei Okayama

Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis

Takanori Suzuki, Kentaro Matsuura, Satoshi Narahara, Kohei Okayama et autres

jp (code pays fourni par la source)

The Initial Therapeutic Response in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Contributes to the Change of Liver Function during Treatment: A Multicenter Analysis

Takanori Suzuki, Ryo Sato, Kentaro Matsuura, Daisuke Kato et autres

INTRODUCTION: Therapeutic response in patients with unresectable hepatocellular carcinoma (HCC) receiving multikinase inhibitors is associated with changes in liver function. However, limited data are available for patients treated with atezolizumab plus bevacizumab (ATZ/BEV). METHODS: We retrospectively enrolled 151 patients with unresectable HCC …

jp (code pays fourni par la source)

The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis

Ryo Sato, Takanori Suzuki, Kentaro Matsuura, Daisuke Kato et autres

ABSTRACT Background There are few reports on the factors that contribute to liver function at the time of disease progression after first‐line systemic therapy for unresectable hepatocellular carcinoma (u‐HCC). Therefore, our multicenter study investigated these factors in u‐HCC patients treated with atezolizumab …

jp (code pays fourni par la source)

The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis

Ryo Sato, Takanori Suzuki, Kentaro Matsuura, Daisuke Kato et autres

INTRODUCTION: Atezolizumab plus bevacizumab (ATZ/BEV) is used for the treatment of unresectable hepatocellular carcinoma (u-HCC). However, there are few reports investigating the predictors of whether or not disease control can be achieved for long periods. METHODS: We enrolled 106 u-HCC patients who …

jp (code pays fourni par la source)

Number of Tumors Stratifies the Therapeutic Response to Atezolizumab plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

Takanori Suzuki, Kentaro Matsuura, Daisuke Kato, Katsumi Hayashi et autres

INTRODUCTION: Atezolizumab plus bevacizumab (ATZ + BV) is used for the treatment of Barcelona Clinic Liver Cancer (BCLC) stage B unresectable hepatocellular carcinoma (u-HCC) patients. However, the efficacy of ATZ + BV in various BCLC stage B conditions, especially the up-to-seven criteria …

jp (code pays fourni par la source)

The Effectiveness of Long-Term Continuation of Atezolizumab plus Bevacizumab in Patients Receiving Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Study

Takanori Suzuki, Kentaro Matsuura, Daisuke Kato, Katsumi Hayashi et autres

INTRODUCTION: Changes in liver function in patients with unresectable hepatocellular carcinoma (u-HCC), following extended periods from the initiation of atezolizumab plus bevacizumab (Atez/Bev), have not been fully investigated. METHODS: Of 148 u-HCC patients treated with first-line Atez/Bev, the study enrolled 38 u-HCC …

jp (code pays fourni par la source)

Neutrophil‐to‐lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis

Takanori Suzuki, Kentaro Matsuura, Satoshi Sobue, Daisuke Kato et autres

BACKGROUND AND AIMS: Durvalumab plus tremelimumab (Dur/Tre) therapy is expected to have good therapeutic efficacy for patients with unresectable hepatocellular carcinoma (u-HCC). We previously reported that the neutrophil-to-lymphocyte ratio (NLR) during atezolizumab plus bevacizumab therapy in u-HCC patients was a useful marker …

jp (code pays fourni par la source)

Pathological Complete Response after Pembrolizumab Treatment for Unresectable Perihilar Cholangiocarcinoma with High Microsatellite Instability: A Case Report

Yoshikuni Inokawa, Hironori Mizuno, Mihoko Yamada, Shoji Kawakatsu et autres

INTRODUCTION: Pembrolizumab has been introduced to solid cancers with microsatellite instability (MSI)-high cases; however, its clinical experience for cholangiocarcinoma remains very limited. Here, we present a case who successfully underwent conversion surgery following pembrolizumab treatment for MSI-high perihilar cholangiocarcinoma, which pathologically exhibited …

jp (code pays fourni par la source)

Poor Tolerability of Lenvatinib in Elderly Patients with Advanced Hepatocellular Carcinoma after Disease Progression following First-Line Atezolizumab Plus Bevacizumab: A Multicenter Study

Daisuke Kato, Takanori Suzuki, Kentaro Matsuura, Kohei Okayama et autres

INTRODUCTION: We investigated the effectiveness of lenvatinib (LEN) after disease progression following first-line treatment with atezolizumab plus bevacizumab (Atez/Bev) in patients with unresectable hepatocellular carcinoma (HCC). METHODS: One hundred and ten HCC patients treated with Atez/Bev as first-line systemic chemotherapy were enrolled …

jp (code pays fourni par la source)

Reintervention of biliary uncovered self‐expandable metallic stent with slim delivery using ultrathin endoscope after left lobectomy

Takayuki Nukui, T Oiwa, Kenji Urakabe, Kohei Okayama et autres

The authors declare no conflict of interest for this article. Video S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to …

jp (code pays fourni par la source)

[Gastric metastasis of breast cancer treated as primary gastric cancer due to difficulty in differentiating primary and metastatic cancer:a case report].

Takayuki Nukui, Akihisa Minowa, Takashi Mizushima, Kenji Urakabe et autres

A female patient in her 50s who underwent chemotherapy for left primary breast cancer presented with cancerous pleurisy and disseminated intravascular coagulation. Esophagogastroduodenoscopy and liver biopsy revealed gastric and liver cancer. Distinguishing between primary and metastatic cancer by pathological findings is difficult …

jp (code pays fourni par la source)

Perivascular Epithelial Cell Tumor of the Pancreas Diagnosed Preoperatively by Endoscopic Ultrasound-guided Fine-needle Aspiration

Konomu Uno, Shuya Shimizu, Katsumi Hayashi, Tomonori Yamada et autres

We herein report a 49-year-old woman with a perivascular epithelial cell tumor (PEComa) of the pancreas. Imaging studies demonstrated a relatively well-demarcated mass, measuring approximately 40 mm in diameter, located in the pancreatic tail. It was heterogeneously enhanced almost to the same …

jp (code pays fourni par la source)